Today: The Synthetic Biologics Inc (SYN) Set to Announce Earnings on Tuesday

The Synthetic Biologics Inc (SYN) Set to Announce Earnings on Tuesday

Synthetic Biologics Inc (NYSE:SYN) is set to issue its Q316 quarterly earnings data on Tuesday, November 1st. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Synthetic Biologics (NYSE:SYN) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. On average, analysts expect Synthetic Biologics to post $-0.39 EPS for the current fiscal year and $-0.52 EPS for the next fiscal year.

Shares of Synthetic Biologics Inc (NYSE:SYN) opened at 1.36 on Monday. The company has a 50 day moving average price of $1.65 and a 200 day moving average price of $1.85. The company’s market capitalization is $124.13 million. Synthetic Biologics Inc has a 12-month low of $0.93 and a 12-month high of $3.09.

A number of analysts have issued reports on SYN shares. Zacks Investment Research downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Thursday, July 7th. Griffin Securities set a $5.80 target price on Synthetic Biologics and gave the stock a “buy” rating in a research note on Wednesday, August 31st. BTIG Research started coverage on Synthetic Biologics in a research note on Thursday, August 25th. They issued a “buy” rating and a $5.00 target price for the company. Finally, FBR & Co reaffirmed a “buy” rating on shares of Synthetic Biologics in a research note on Friday, August 5th.

Institutional investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. acquired a new position in Synthetic Biologics during the second quarter worth $106,000. State Street Corp boosted its position in Synthetic Biologics by 1,530.4% in the second quarter. State Street Corp now owns 874,463 shares of the company’s stock worth $1,573,000 after buying an additional 820,829 shares in the last quarter. Rhumbline Advisers acquired a new position in Synthetic Biologics during the second quarter worth $126,000. Teachers Advisors Inc. acquired a new position in Synthetic Biologics during the second quarter worth $216,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Synthetic Biologics by 53.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,779,542 shares of the company’s stock worth $3,203,000 after buying an additional 622,316 shares in the last quarter.

Synthetic Biologics Company Profile

Related posts

Leave a Comment